What Is CGRP? The Science Behind Post-Traumatic Migraine

Amar Lunagaria — Co-Founder & Chief Pharmacist, LienScripts | March 26, 2024 | 9 min read

CGRP — calcitonin gene-related peptide — is the key molecule responsible for migraine attacks. Post-traumatic migraine after accidents occurs because head and neck trauma triggers the same CGRP-driven trigeminal pathway that causes spontaneous migraine. Understanding CGRP explains why modern migraine medications work — and why they matter in PI cases.

What Is CGRP? The Science Behind Post-Traumatic Migraine

When a neurologist prescribes Qulipta, Aimovig, or Nurtec ODT for a personal injury patient's headaches, they are targeting a specific molecule called CGRP — calcitonin gene-related peptide. Understanding what CGRP is, why it causes migraine, and why trauma triggers it gives PI attorneys a clear clinical basis for explaining why these modern, expensive medications are medically necessary.

[!KEY] CGRP (calcitonin gene-related peptide) is the specific molecule elevated by head and neck trauma that drives post-traumatic migraine — a neurologist's CGRP prescription is both a treatment and a documented, mechanism-specific injury consequence.

What Is CGRP?

CGRP is a neuropeptide — a small protein released by nerve cells — that plays a central role in pain signaling in the head and neck. It is found in high concentrations in the trigeminal nerve, which is the primary sensory nerve for the face, scalp, and meninges (the membranes surrounding the brain).

During a migraine attack, CGRP is released from trigeminal nerve endings in large quantities. This release:

1. Dilates blood vessels in the meninges, stretching pain-sensitive structures
2. Activates CGRP receptors on trigeminal nerve cells, amplifying pain signals
3. Creates neurogenic inflammation — local inflammation driven by nerve activity rather than tissue injury
4. Sensitizes the trigeminal pain pathway — making the patient hypersensitive to light, sound, movement, and touch

Blood levels of CGRP are measurably elevated during migraine attacks and return to baseline between attacks. This is not a theoretical mechanism — CGRP can be measured in blood during attacks, and blocking CGRP reduces attacks.

How Head and Neck Trauma Triggers CGRP Release

Normal spontaneous migraine occurs when CGRP is released from the trigeminal nerve for internal reasons (hormonal changes, stress, sleep disruption, certain foods). Post-traumatic migraine occurs when mechanical trauma to the head and neck causes direct activation of trigeminal nerve fibers, triggering the same CGRP-release cascade.

The trigeminal nerve is intimately connected to the cervical (neck) nerve roots through a structure called the trigeminocervical complex in the brainstem. This connection is why:

• Whiplash injuries — which strain the cervical musculature and can injure cervical nerve roots — frequently trigger migraine
• Direct head trauma — concussion, scalp laceration, or skull impact — activates trigeminal nerve fibers directly
• Cervical disc injury — herniated or bulging discs at C1-C4 can irritate cervical nerve roots that feed directly into the trigeminocervical complex

The trauma creates a state of sensitization in the trigeminal pain pathway — the same neurological state that underlies chronic migraine. Once sensitized, the pathway responds to much lower provocation thresholds. The accident has, in effect, reprogrammed the migraine threshold.

[!KEY] The mechanism linking whiplash to post-traumatic migraine runs through the trigeminocervical complex — a specific anatomical connection between cervical nerve roots and the trigeminal pain pathway — which means a cervical spine injury documented in imaging can directly support the neurologist's CGRP prescription as mechanism-consistent treatment.

Why Post-Traumatic Migraine Is Distinct From "Normal Headache"

A common defense argument is that post-accident headaches are just "regular headaches" that would have occurred anyway. The CGRP mechanism explains why this is wrong:

The sensitization is traumatically induced. The trigeminal pathway was sensitized by the mechanical trauma of the accident. Before the accident, the pathway had a higher threshold — it did not respond with migraine to minor stimuli. After the accident, the lowered threshold produces migraine from stimuli that previously caused no response.

The mechanism is measurable. CGRP levels in blood and cerebrospinal fluid can be measured. The medication works — CGRP antagonists reduce migraine frequency by blocking the specific molecule elevated by the accident. If the headaches were unrelated to the injury, the CGRP-targeted medications would not work.

The diagnosis requires neurological assessment. A neurologist who diagnoses post-traumatic migraine and prescribes a CGRP-targeting medication is making a clinical determination — documented in their records — that the patient's migraine condition meets the diagnostic criteria for post-traumatic migraine attributable to the accident.

The CGRP Drug Classes: How They Work

Two major drug classes now target CGRP:

Oral Gepants (CGRP Receptor Antagonists)

Qulipta (atogepant), Nurtec ODT (rimegepant), Ubrelvy (ubrogepant), Zavzpret (zavegepant nasal spray)

These small molecules block the CGRP receptor — the molecular target that CGRP binds to on trigeminal nerve cells. By blocking this receptor:

• The CGRP signal cannot be received
• Vasodilation and neurogenic inflammation are prevented
• Pain pathway sensitization is reduced

Gepants work quickly and can be used for both acute treatment (blocking an active attack) and prevention (blocking the sensitization process when taken regularly).

Monoclonal Antibodies (CGRP Pathway Antibodies)

Aimovig (erenumab), Emgality (galcanezumab), Ajovy (fremanezumab), Vyepti (eptinezumab)

These large-molecule biologics target either:

• The CGRP molecule itself (galcanezumab, fremanezumab, eptinezumab) — binding to CGRP before it can reach the receptor
• The CGRP receptor (erenumab) — blocking the receptor directly

Antibodies are injected monthly or quarterly and provide sustained, passive blockade of the CGRP pathway throughout the dosing interval. They work preventively, not acutely — reducing how often migraines occur rather than stopping attacks in progress.

Why These Medications Establish Injury Causation

When a neurologist prescribes a CGRP-targeting medication for a PI patient, they are documenting:

1. Diagnosis of migraine — specifically attributed to or worsened by the accident
2. Mechanism-specific treatment — the drug class chosen is the one that specifically targets the molecule elevated by head and neck trauma
3. Clinical assessment that CGRP pathway involvement is present — the prescriber has determined that CGRP-mediated sensitization is driving the patient's headaches
4. Ongoing injury consequence — monthly refills document continued migraine burden requiring pharmacological management

For PI attorneys, a CGRP prescription from a neurologist is among the most scientifically defensible treatment records available. The mechanism is precisely understood, the causal chain from trauma to CGRP release to migraine is well-established in the neuroscience literature, and the drug class's efficacy is proven in clinical trials — all pointing to a documented, mechanism-specific injury consequence.

[!TIP] For Attorneys: A CGRP prescription from a neurologist is among the strongest causation documents in PI — the drug class specifically targets the molecule elevated by trauma, and the prescription itself documents that a mechanism-specific injury consequence is present.

The Pre-Existing Migraine Question

Some PI patients had migraine before their accident. Defense attorneys argue this means the CGRP medications are pre-existing, not accident-related.

The response: even in patients with pre-existing migraine, trauma can significantly worsen migraine frequency and severity through the same CGRP sensitization mechanism. A patient who had occasional migraines (2-3 per month) before the accident who now has chronic migraine (15+ days per month) has suffered a documented, trauma-induced worsening. The CGRP medications document that worsening — the patient previously managed without a CGRP preventive but now requires one.

The aggravation of pre-existing condition is a well-established damages category. CGRP medication documentation is direct evidence of that aggravation.

[!KEY] For clients with pre-existing migraine, the correct damages framing is aggravation — the pharmacy record before the accident (no CGRP preventive) versus after the accident (CGRP preventive required) is the clearest possible before-and-after document of trauma-induced worsening.

LienScripts provides pharmacy lien coverage for Qulipta, Nurtec ODT, Aimovig, Emgality, Ajovy, and all CGRP medications at $0 upfront cost for qualified PI patients. Contact LienScripts.

Related Resources

• CGRP Medications for Post-Traumatic Migraine in Personal Injury Cases
• Qulipta vs. Nurtec ODT: Which CGRP Gepant Is Right for PI Patients?
• Aimovig, Emgality, Ajovy, and Vyepti: Injectable CGRP Antibodies for PI